Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
3 extracted signals · 2 resolved · 1 still active
Parkev Tatevosian, CFA30 Jan 2026, 23:34 UTC
AI-generated source summary
The pharmaceutical industry is facing pressure from the current administration to lower prices and increase access to medications. Despite this, three major companies – Pfizer, Novo Nordisk, and Eli Lilly – are identified as undervalued. Pfizer is trading at $25.60 with an intrinsic value of over $80. Novo Nordisk is trading at $62.53, with an intrinsic value of $82.64, and also has a first-to-market oral pill for weight loss. Eli Lilly is trading near its 52-week high at $1,068.97, with an intrinsic value of $1,600, and has shown exceptional performance. All three are rated as buy, with Eli Lilly being the top pick for 2026.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Signals in this source
More Prediction Case Files from Parkev Tatevosian, CFA
Coca-Cola Stock: Buy, Hold, or Sell? | KO Stock Analysis
SoFi Stock Analysis: Buy the Dip?
Should You Buy Micron Stock Instead of Nvidia Stock? | MU Stock vs. NVDA Stock
Should You Buy the Dip in Meta Stock? | META Stock Analysis and Live Earnings Review
Should Passive Income Investors Buy Colgate Palmolive Stock?
Procter & Gamble Stock: Buy, Hold, or Sell? | PG Stock Analysis
Parkev Tatevosian, CFA
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.